Ranbaxy determined to restore "rightful" place with GMP compliance efforts, says CEO
This article was originally published in Scrip
Ranbaxy's CEO and managing director Arun Sawhney says that the company is determined to find its rightful place in the minds of regulators and customers after a string of recent GMP compliance setbacks, including a US FDA import alert against its Mohali facility in 2013.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.